A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is?

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 4, 2008, Pages 313-328

  Pierangeli, Silvia S ^a   Harris, E Nigel ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; ELISA

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LIPOCORTIN 5; LUPUS ANTICOAGULANT;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ABORTION, HABITUAL; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; PREGNANCY; THROMBIN; THROMBOSIS;

EID: 50249154439     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1085473     Document Type: Review

References (136)

1. Harris EN. Antiphospholipid syndrome. In: Klippel JH, Dieppe PA, eds. Rheumatology. London, United Kingdom: Mosby-Year Book; 1994:32.1-32.6
2. Harris EN. Syndrome of the Black Swan. Br J Rheumatol 1987;26:324-326
3. 2glycoprotein I enhances cardiolipoin-binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 1992;82:565-570
4. 2glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4124
5. 2glycoprotein I in the absence of phospholipid. J Immunol 1995;154:954-960
6. Triplett DA, Brandt JT. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon. Hematol Pathol 1988;2:121-143
7. Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis; type, incidence, and cause. J Am Med Assoc 1952;150:467-473
8. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952;31:621-622
9. Conley CL. Disorders of the blood in disseminated lupus erythematosus. Am J Med 1952;13:1-2
10. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972;1:75-95
11. Bowie EJ, Thompson JH Jr, Pascuzzi CA, Owen CA Jr. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963;62:416-430
12. Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980;92:156-159
13. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;26:1211-1214
14. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibody isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6
15. Mouritsen S, Hoier-Madson M, Wiik A, Orum O, Strandberg Pedersen N. The specificity of anti-cardiolipoin antibodies from syphilis patient and from patients with systemic lupus erythematosus. Clin Exp Immunol 1989;76:178-183
16. Harris EN, Gharavi AE, Wasley GD, Hughes GRV. Use of enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis 1988;157:23-31
17. Intrator L, Oksenhendler E, Desforges L. Anticardiolipin antibodies in HIV infected with or without autoimmune thrombocytopenia purpura. Br J Haematol 1988;67:269-270
18. Canoso RE, Zon LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol 1987;65:495-498
19. Galvez J, Martin I, Medino D, Pujol E. Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies. Med Clin (Barc) 1997;108:396-397
20. Canoso RT, Sise HS. Chlorpromazin-induced lupus anticoagulant and associated immunologic anormalitis. Am J Hematol 1982;13:121
21. Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990;74:1-9
22. Galli M, Comfurius P, Maasen C, Hamker HC, Debates MH. van Breda-Vriesman. Anticardiolipin (ACA) antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;336:1544-1547
23. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;336:1547
24. 2glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4124
25. 2glycoprotein I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985;54:397-401
26. Harris EN, Gharavi AE, Patel S, Hughes GRC. Evaluation of the anticardiolipin antibody test: report of an international workshop held April 4 1986. Clin Exp Immunol 1987;68:215-222
27. Harris EN. The second international anticardiolipin standardization workshop: the Kingston Anticardiolipin Antibody Study (KAPS) group. Am J Clin Pathol 1990;101:616-624
28. th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998;25:156-162
29. Reber G, Arvieux J, Comby D, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemost 1995;73:444-452
30. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report: Vth International Symposium on Antiphospholipid Antibodies. Am J Clin Pathol 1994;101:616-624
31. Derksen W, Erkan D, Kaplan V, Sammaritano L, Pierangeli SS, Lockshin MD. Real world experience with antiphospholipid antibodies (APL): how stable are APL over time? [abstract]. Arthritis Rheum 2004;50:S67
32. De Moerloose P, Reber G, Vogel J-J. Anticardiolipn antibody determination: comparison of three ELISA assays. Clin Exp Rheumatol 1990;8:575-577
33. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002;118:548-557
34. Wong RCW, Wilson RJ, Pollock W, Steele RH, Gillis D. Anticardiolipin antibody testing and reporting practices among laboratories participating in a large external quality assurance program. Pathology 2004;36:174-181
35. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001;86:575-583
36. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002;11:269-275
37. Peaceman AH, Silver RK, MacGregor SN, Scool ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992;144:1780-1784
38. Pierangeli SS, Gharavi MD, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. Clin Obstet Gynecol 2001;44:48-57
39. Kutteh WH, Franklin RD. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers. Am J Obstet Gynecol 2004;191:440-448
40. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309-1311
41. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306
42. Harris EN, Chan JKH, Asherson R, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss and thrombocytopenia: predictive value of the anti-cardiolipin test. Arch Intern Med 1986;146:2153-2156
43. Escalante A, Brey RL, Mitchel BD, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995;98:558-567
44. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. Stroke 1997;28:1660-1665
45. Silver RM, Porter TF, VanLeeuween I, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: clinical consequences of "low titers." Obstet Gynecol 1996;87:494-500
46. Budd R, Harley E, Quarshie A, Henderson V, Harris EN, Pierangeli SSA. Re-appraisal of the normal cut-off assignment for anti-cardiolipin IgM tests. J Thromb Haemost 2006;4:2210-2214
47. 2glycoprotein I. Br J Haematol 1992;81:568-573
48. Harris EN, Gharavi AE, Loizou S, et al. Cross-reactivity of antiphospholipid antibodies. J Clin Lab Immunol 1985;16:1-6
49. Oosting JD, Derksen RH, Bobbink IW, Hackeng JM, Bouma BN, deGroot PC. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-2625
50. Bevers E, Galli M, Barbui T, Comfurius P, Zwaal RD. Lupus anticoagulant IgG's (LA) are not directed to phospholipid only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-632
51. Atsumi AT, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies - are they worth assaying?. Thromb Res 2004;114:L533
52. 2glycoprotein I antibodies. Arthritis Rheum 1999;42:2461-2470
53. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-715
54. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002;126:1424-1429
55. Wong RCW, Adelstein S, Gillis D, Favaloro EJ. Development of consensus guidelines for anticardiolipin antd lupus anticoagulant testing. Semin Thromb Hemost 2005;31:39-48
56. Wilson WA, Faghri Z, Taheri Z, Gharavi AE. Significance of IgA antiphospholipid antibodies. Lupus 1998;7(Suppl 2):S110
57. Selva-O'Callaghan A, Ordi-Ros J, Monegal-Ferran F, et al. IgA anticardiolipin antibodies - relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998;79:282-285
58. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. Medicine 1989;68:353-365
59. Spadaro A, Riccieri V, Terracina S, Rinaldi T, Taccari E, Zoppini A. Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus 2000;9:56-60
60. Weidmann CE, Wallace DJ, Peter JB, Knight PJ, Bear MB, Klinenberg JR. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol 1988;15:74-79
61. Wilson WA, Faghiri Z, Taheri F, Gharavi AE. Significance of IgA antiphospholipid antibodies. Lupus 1988;7(Suppl 2):S110-S113
62. Lopez LR, Santos M, Espinoza LR, La Rosa F. Clinical significance of immunoglobulin A: versus immunoglobulins G and M anticardiolipin antibodies in patients with systemic lupus erythematosus: correlation with thrombosis, thrombocytopenia and recurrent abortion. Coag Transf Med 1992;98:449-454
63. Molina JF, Gutierrez-Urena S, Molina J, et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997;7:291-296
64. Wong KL, Liu HW, Ho K, Chan K, Wong R. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol 1991;18:1187-1192
65. 2glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999;318:53-60
66. Tajim C, Suzuki Y, Mizushima Y, Ichikawa Y. Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. J Rheumatol 1998;25:1730-1737
67. Kalunian KC, Peters JB, Middlekauff HR, et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988;85:602-608
68. Bahar AM, Kwak JY, Beer AE, et al. Antibodies to phospholipids and nuclear antigens in non-pregnant women with unexplained spontaneous recurrent abortions. J Reprod Immunol 1993;24:213-222
69. Pierangeli SS, Liu X, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995;74:1361-1367
70. 2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol 2003;102:294-300
71. Walton SP, Pierangeli SS, Campbell A, Klein E, Burchitt B, Harris EN. Demonstration of antiphospholipid antibodies heterogeneity by phospholipid column chromatography and salt gradient elution. Lupus 1995;4:263-271
72. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br J Med 1983;287:1021-1023
73. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/ Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995;74:1597-1603
74. Brandt JT, Triplett DA, Rock WA, Bovill EG, Arkin CF. Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program. Arch Pathol Lab Med 1991;115:109-114
75. Brandt JT, Triplett DA, Musgrave K, Orr C. The sensitivity of different coagulation reagents to the presence of lupus anticoagulants. Arch Pathol Lab Med 1987;111:120-124
76. Denis-Magdelaine A, Flahault A, Verdy E. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants. Haemostasis 1995;25:98-105
77. Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisloff F. The Lupus Ratio test - an interlaboratory study on the detection of lupus anticoagulants by an APTT-based-integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants-ISLA 5. Thromb Haemost 2000;83:704-708
78. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-1832
79. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a meta-analysis. J Rheumatol 2006;33:2214-2221
80. McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989;73:506-513
81. Chamley LW, Pattison NS, McKay EJ. Separation of lupus anticoagulant from anticardiolipin antibodies by ion exchange and gel filtration chromatography. Haemostasis 1991;21:25-29
82. Derksen RH, Hasselaar P, Blokzijl L, Gmelig Meyling FH, deGroot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988;47:364-371
83. Nash MJ, Camilleri RS, Kunka S, Mackie IJ, Machin SJ, Cohen H. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost 2004;2:1077-1081
84. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-1190
85. The Lupus Anticoagulant Working Party. Detection of lupus like anticoagulant: current laboratory practice in the United Kingdom. J Clin Pathol 1990;43:73-75
86. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991;65:320-322
87. Lupus Anticoagulant Working Party, on behalf of the BCSH Haemostasis and Thrombosis Task Force. Guidelines on Haemostasis and Thrombosis Task Force. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991;44:885-889
88. Exner T, Triplett DA, Taberner DA, Howard MA, Harris EN. Comparison of test methods for the lupus anticoagulant: international survey on lupus anticoagulants-1 (ISLA-1). Thromb Haemost 1990;64:478-484
89. Hemostasis Committee of the. "Societe Francaise de Biologie Clinique." Laboratory heterogeneity of the lupus anticoagulant: a multicentre study using different clotting assays on a panel of 78 samples. Thromb Res 1992;66:349-364
90. Working Group on Hemostasis of the Societe Francaise de Biologie Clinique. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Thromb Haemost 1993;70:781-786
91. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants. On behalf of the subcommittee in Lupus Anticoagulants/ Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995;74:1597-1603
92. Goudemand J, Caron C, De Prost D, et al. Evaluation of sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants. The Working Group on Hemostasis of the Societe Francaise of Biologie Clinicque and for the Groupe d'Etudes surl Hemostase et la Thrombose. Thromb Haemost 1997;77:336-342
93. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for lupus anticoagulant: an analysis of results from three survey of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997;77:934-937
94. 2glycopotein I. Thromb Haemost 1999;81:929-934
95. Tripodi A, Biosiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity purified immunoglobulin with LA activity. Clin Chem 2003;49:1608-1614
96. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE. Lupus anticoagulant testing: improvements in performance in an UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002;119:364-369
97. Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004;104:2783-2790
98. Rote NS, Dostal-Johnson D, Branch DW. Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin and antibodies against phosphatidylserine and cardiolipin. Am J Obstet Gynecol 1990;163:575-584
99. Harris EN, Pierangeli SS. A more specific ELISA assay for the detection of antiphospholipid. Clin Immunol Newsl 1995;15:26-28
100. Merkel P, Chang Y, Pierangeli SS, Harris EN, Polisson RP. Comparison between the standard anticardiolipin antibody test and a new phospholipids test in patients with connective tissue diseases. J Rheumatol 1999;26:591-596
101. 2glycoprotein I in the absence of phospholipid: importance of antigen density and bivalent binding. J Immunol 1995;154:954-960
102. 2glycoprotein I antibodies: a marker of antiphospholipid syndrome?. Lupus 1995;4:122-130
103. 2glycoprotein I. Br J Haematol 1992;81:568-573
104. 2glycoprotein with lupus circulating anticoagulant and thrombosis in SLE. Am J Med 1992;93:181-186
105. 2glycoprotein 1 than with antiphospholipid antibodies. J Rheumatol 1995;22:1899-1906
106. 2glycoprotein 1 in patients with antiphospholipid syndrome. J Clin Lab Anal 1998;12:293-297
107. 2glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996;11:509-512
108. 2glycoprotein antibodies: detection and association with thrombosis. Br J Haematol 1995;89:397-402
109. 2glycoprotein antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance. Lupus 1996;5:587-592
110. 2glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466-1474
111. 2glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457-462
112. 2glycopotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-2723
113. 2GPI) test? [abstract]Arthritis Rheum 2004:S67
114. 2glycopotein I contribute to the better characterization of the antiphospholipid syndrome? Lupus 1999;8:430-438
115. 2glycopotein I antibody provide additional information in patients with thrombosis. Thromb Res 2003;111:29-32
116. 2glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002;88:66-73
117. 2glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004;2:1860-1862
118. 2GPI autoantibodies by ELISA. J Autoimmun 2002;18:289-297
119. 2glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta glycoprotein I antibodies. J Thromb Haemost 2006;4:1619-1621
120. 2glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and kala-azar. Clin Exp Rheumatol 2001;19:425-430
121. Pierangeli SS, Henderson V, Pappalardo E, et al. Evaluation of several ELISA tests used in the diagnosis of antiphospholipid syndrome in a large cohort of patient samples. [abstract]. Arthritis Rheum 2006;54:S553
122. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996;66:540-546
123. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 2002;17:2981-2985
124. Sugi T, McIntyre JA. Certain autoantibodies to phosphatidylethanolamine (aPE) recognized factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001;17:207-214
125. Rao LVM, Hoang AD, Rapaport SI. Differences in interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Thromb Haemost 1995;73:668-674
126. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in antiphospholipid syndrome. Blood 2006;107:4375-4382
127. Atsumi A, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies - are they worth assaying? Thromb Res 2004;114:L533-L538
128. De Groot PG, Lutters B, Derksen RH, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005;3:1993-1997
129. 2glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-2723
130. Bizzaro N, Ghirardello A, Zampieri S, et al. Antiprothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007;5:1158-1164
131. 2glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 2005;3:1231-1238
132. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007;110:1178-1183
133. Hudson M, Herr AL, Rauch J, et al. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 2003;30:2385-2391
134. 2glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001;47:1008-1015
135. 2glycoprotein I cause LA, and their presence correlates strongly with thrombosis. Blood 2005;105:1540-1545
136. 2glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007;56:280-290